Chalmers_2009_J.Neurol_256_717

Reference

Title : Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease - Chalmers_2009_J.Neurol_256_717
Author(s) : Chalmers KA , Wilcock GK , Vinters HV , Perry EK , Perry R , Ballard CG , Love S
Ref : Journal of Neurology , 256 :717 , 2009
Abstract :

Cholinesterase inhibitors (ChEIs) are widely used for the symptomatic treatment of Alzheimer's disease (AD). In vitro and in animal studies, ChEIs have been shown to influence the processing of Abeta and the phosphorylation of tau, proteins that are the principal constituents of the plaques and neurofibrillary tangles, respectively, in AD brain. However, little is known about the effects of these drugs on Abeta and tau pathology in AD. Using avidin-biotin immunohistochemistry and computer-assisted image analysis, we compared Abeta and tau loads in the frontal and temporal cortices of 72 brains from matched cohorts of AD patients who had or had not received ChEIs. Patients treated with ChEIs had accumulated significantly more phospho-tau in their cerebral cortex than had untreated patients (P = 0.004). Abeta accumulation was reduced but not significantly. These data raise the possibility that increased tau phosphorylation may influence long-term clinical responsiveness to ChEIs.

PubMedSearch : Chalmers_2009_J.Neurol_256_717
PubMedID: 19240967

Related information

Citations formats

Chalmers KA, Wilcock GK, Vinters HV, Perry EK, Perry R, Ballard CG, Love S (2009)
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease
Journal of Neurology 256 :717

Chalmers KA, Wilcock GK, Vinters HV, Perry EK, Perry R, Ballard CG, Love S (2009)
Journal of Neurology 256 :717